New Zealand Data Sheet

1. PRODUCT NAME

Lithium Carbonate 250 mg Capsule.

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each Lithium Carbonate capsule contains 250 mg of lithium carbonate.

**Excipient(s) with known effect**

Lithium Carbonate capsules contain lactose monohydrate.
For the full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM

Size one capsule with a clear body and a green cap containing white powder.

4. CLINICAL PARTICULARS

4.1. Therapeutic indications

- Treatment of mania and hypomania.
- Treatment of some patients with recurrent bipolar depression, for which treatment with other antidepressants have been unsuccessful.
- Prophylactic treatment of recurrent affective disorders.

4.2. Dose and method of administration

**Dose**

A simple treatment schedule has been evolved which, except for some minor variations, should be followed whether using Lithium Carbonate therapeutically or prophylactically. The minor variations to this schedule depend on the elements of the illness being treated and these are described later.

1. In patients of average weight (70 kg) an initial dose of 400-1,200 mg of Lithium Carbonate may be given as a single daily dose in the morning or on retiring. Alternatively, the dose may be divided and given morning and evening. When changing from other lithium preparations serum lithium levels should first be checked, then Lithium Carbonate therapy commenced at a daily dose as close as possible to the dose of the other form of lithium. As bioavailability varies from product to product (particularly with regard to retard or slow-release preparations), a change of product should be regarded as initiation of new treatment.
2. Four to five days after starting treatment (and never longer than one week) a blood sample should be taken for the estimation of serum lithium level.

3. The objective is to adjust the Lithium carbonate dose to maintain the serum lithium level permanently within the diurnal range of 0.5 – 1.5 mmol/L. In practice, the blood sample should be taken between 12 and 24 hours after the previous dose of Lithium carbonate. ‘Target’ serum lithium concentrations at 12 and 24 hours are shown in Table 1. Serum lithium levels should be monitored weekly until stabilisation is achieved.

<table>
<thead>
<tr>
<th></th>
<th>At 12 hours</th>
<th>At 24 hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>Once daily dosage</td>
<td>0.7 – 1.0</td>
<td>0.5 – 0.8</td>
</tr>
<tr>
<td>Twice daily dosage</td>
<td>0.5 – 0.8</td>
<td></td>
</tr>
</tbody>
</table>

4. Lithium therapy should not be initiated unless adequate facilities for routine monitoring of serum concentrations are available. Following stabilisation of serum lithium levels, the period between subsequent estimations can be increased gradually but should not normally exceed three months. Additional measurements should be made following alteration of dosage, on development of intercurrent disease, signs of manic or depressive relapse, following significant change in sodium or fluid intake, or if signs of lithium toxicity occur.

5. Whilst a high proportion of acutely ill patients may respond within three to seven days of the commencement of Lithium carbonate therapy, Lithium carbonate should be continued through any recurrence of the affective disturbance. This is important as the full prophylactic effect may not occur for 6 to 12 months after the initiation of therapy.

6. In patients who show a positive response to Lithium Carbonate therapy, treatment is likely to be long term. Careful clinical appraisal of the patient should be exercised throughout medication (see section 6.6).

**Treatment of Acute Mania, Hypomania and Recurrent Bipolar Depression**

It is likely that a higher-than-normal Lithium Carbonate intake may be necessary during an acute phase and divided doses would be required here. Therefore, as soon as control of mania or depression is achieved, the serum lithium level should be determined and it may be necessary, dependent on the results, to lower the dose of Lithium Carbonate and re-stabilise serum lithium levels. In all other details the described treatment schedule is recommended.

**Prophylactic Treatment of Recurrent Affective Disorders**

It is recommended that the described treatment schedule is followed.

**Elderly Population**

In elderly patients or those below 50 kg in weight, it is recommended that the starting dose be 400 mg. Elderly patients may be more sensitive to undesirable effects of lithium and may also
require lower doses in order to maintain normal serum lithium levels. It follows therefore that long term patients often require a reduction in dosage over a period of years.

**Children and Adolescents**

Not recommended.

**Renal impairment**

Lithium is contraindicated in patients with significant renal disease (see Section 4.3).

**Method of Administration**

Lithium should be taken with food, as it causes less nausea than on an empty stomach.

**4.3. Contraindications**

- Patients with significant cardiovascular disease
- Patients with significant renal disease
- Untreated hypothyroidism
- Conditions associated with hyponatremia, for example: Addison’s disease, dehydrated or severely debilitated patients, patients on low sodium diets
- Hypersensitivity to lithium or any of the excipients contained in the capsule
- Breastfeeding

**4.4. Special warnings and precautions for use**

**General**

When considering lithium therapy, it is necessary to ascertain whether patients are receiving lithium in any other form. If so, check serum levels before proceeding. It is important to ensure that renal function is normal – if necessary, a creatinine clearance test or other renal function test should be performed. Cardiac, thyroid and parathyroid (parathyroid hormone and serum calcium level) function should be assessed before commencing lithium treatment. Patients should be euthyroid before the initiation of lithium therapy. Renal function, cardiac function, thyroid and parathyroid function should be reassessed periodically. Care should be taken in the presence of Encephalopathic syndrome or intercurrent infection.

Clear instructions regarding the symptoms of impending toxicity should be given by the doctor to all patients receiving long term lithium therapy (see Lithium toxicity, below). Patients should also be warned to report if polyuria or polydipsia develop. Episodes of nausea and vomiting or other conditions leading to salt/water depletion (including severe dieting) should also be reported. Elderly patients are particularly liable to lithium toxicity.

Caution should be exercised to ensure that diet and fluid intake are normal, thus maintaining a stable electrolyte balance. This may be of special importance in very hot weather or work environment. Infectious diseases including colds, influenza, gastro-enteritis and urinary infections may alter fluid balance and thus affect serum lithium levels. Treatment should be
discontinued during any intercurrent infection and should only be reinstituted after the patient’s physical health has returned to normal.

**Lithium toxicity**

Patients receiving lithium therapy and their family members should be taught to recognise the symptoms of early toxicity and, should these occur, to discontinue therapy and request medical aid at once (see section 4.9).

Symptoms of lithium toxicity may include the following:

1. Gastrointestinal symptoms such as anorexia, diarrhoea and vomiting.
2. Central nervous symptoms such as muscle weakness, lack of co-ordination, drowsiness or lethargy progressing to giddiness or ataxia, tinnitus, blurred vision, dysarthria, coarse tremor and muscle twitching.

At blood levels above 2 -3 mmol/L there may be a large output of dilute urine, with increasing disorientation, seizures, coma and death.

Lithium toxicity is closely related to serum lithium concentrations and can occur at doses close to therapeutic concentrations. For monitoring recommendations of lithium serum levels (see section 4.2).

**Monitoring recommendations**

**Pre-treatment**

Physical examination and laboratory testing are required prior to commencement of therapy and should be repeated at frequent intervals.

Since lithium is excreted primarily by the kidney, adequate renal function is essential in order to avoid lithium accumulation and intoxication. If necessary, a creatinine clearance test or other renal function test should be performed.

Cardiac, thyroid and parathyroid (parathyroid hormone and serum calcium level) function should be assessed before commencing lithium treatment. Thus, a decision to initiate lithium therapy should be preceded by a thorough clinical examination and evaluation of each patient, including laboratory determinations, ECG, and a very careful assessment of renal function.

**On treatment**

See general section

**Renal impairment**

Chronic lithium therapy may be associated with diminution of renal concentrating ability, occasionally presenting as nephrogenic diabetes insipidus with polyuria and polydipsia. Such patients should be carefully managed to avoid dehydration with resulting lithium retention and
toxicity. This condition is usually reversible when lithium is discontinued. The minimum clinically effective dose of lithium should always be used. Morphologic changes with glomerular and interstitial fibrosis and nephron atrophy have also been reported in patients on chronic lithium therapy. High serum concentrations of lithium including episodes of acute lithium toxicity may aggravate these changes. Renal function should be monitored in all patients, not just those with polyuria or polydipsia, e.g. with measurement of blood urea, serum creatinine and urinary protein levels, in addition to the routine serum lithium estimations. When kidney function is assessed, routine urinalysis and other tests may be used to evaluate tubular function (e.g. urine specific gravity, osmolality following water deprivation or 24-hour urine volume) and glomerular function. Of note, acute renal failure has been reported rarely with lithium toxicity. Patients should be instructed to report any symptoms of polyuria, polydipsia, nausea or vomiting.

**Fluid/electrolyte balance**

Vomiting, diarrhoea, intercurrent infection, fluid deprivation and drugs likely to upset electrolyte balance, such as diuretics, may all reduce lithium excretion thereby precipitating intoxication. Therefore, reduction in the dosage of lithium may be required. Lithium requirements may change during fever, infection, and when mood swings occur. Patients in a manic state seem to have increased tolerance to lithium which decreases when manic symptoms subside. Patients should avoid low-salt dietary regimens or other dietary changes which may reduce sodium intake, or circumstances which may cause excessive sodium loss such as heavy exercise leading to excessive sweating as these may lead to increased lithium concentrations.

The patient, therefore, should maintain a normal diet with adequate salt and fluid intake during therapy.

**Hypercalcaemia and Hyperparathyroidism**

Systematic review indicates that about 10% of patients taking lithium long-term develop hypercalcaemia with or without hyperparathyroidism. Patients should be checked for parathyroid function prior to commencing treatment.

Serum calcium levels should be monitored at least yearly in all patients taking lithium. Monitoring should be more frequent if an abnormal result is found, or the patient has a family history of endocrine disease.

If serum calcium levels are raised the serum parathyroid level should be measured. If both parathyroid hormone levels and calcium levels are elevated the patient should be referred for specialist treatment.

In cases of mild hypercalcaemia with normal parathyroid hormone levels, treatment may be continued if the benefits are considered to outweigh the risks, but calcium levels should be monitored more frequently.
If serum calcium levels rise above 11 mg/dL lithium treatment should be stopped and calcium levels measured weekly for the next 4 weeks to ensure that levels drop back to normal.

Patients who have undergone parathyroidectomy in the past may experience recurrent hyperparathyroidism on lithium treatment; serum calcium and parathyroid hormone levels should be carefully monitored.

**Electroconvulsive therapy**

Lithium should be temporarily discontinued before electroconvulsive therapy (ECT) to reduce the risk of delirium, which may occur when the two treatments are co-administered.

**Surgery**

It is wise to discontinue lithium for 24 hours before any major operation. Provided serum electrolytes are in balance it can, and normally should, be restarted soon after the operation. Complete discontinuation of prophylactic lithium therapy should be discussed between patient, general practitioner and specialist.

**Children**

Information regarding the safety and efficacy in children under 12 years of age is not available, therefore lithium therapy is not recommended in this age group.

**Elderly patients**

Lithium should be used with care in the elderly as excretion may be reduced, resulting in a longer half-life. The elderly may, therefore, exhibit signs of toxicity at serum concentrations ordinarily tolerated by younger patients. Elderly patients also often require lower lithium dosages to achieve therapeutic serum concentrations.

**4.5. Interaction with other medicines and other forms of interaction**

If one of the following medicines is initiated, regular monitoring of serum lithium levels for signs of lithium toxicity should be performed during concomitant treatment. Lithium dosage should either be adjusted, or concomitant treatment stopped, as appropriate.

**Interactions that may increase lithium concentrations**

- Selective Serotonin Re-uptake Inhibitors (SSRIs)
- Metronidazole
- Tetracyclines
- Non-steroidal anti-inflammatory drugs (NSAID)
- ACE inhibitors
- Thiazide diuretics (may cause a paradoxical antidiuretic effect resulting in possible water retention and lithium intoxication)
- Spironolactone
- Frusemide
- Angiotensin-II receptor antagonists
- Other drugs affecting electrolyte balance may alter lithium excretion, e.g. steroids

**Interactions that may decrease lithium concentration**

- Xanthines (theophylline, caffeine)
- Sodium bicarbonate and sodium chloride containing products
- Psyllium or ispaghula husk
- Urea
- Mannitol
- Acetazolamide
- Empagliflozin
- Dapagliflozin

**Interactions that may cause neurotoxicity**

- Neuroleptics (risperidone, clozapine, phenothiazines, and particularly haloperidol) may lead to, in rare cases, neurotoxicity in the form of confusion, disorientation, lethargy, tremor, extra-pyramidal symptoms and myoclonus. In some instances, the syndrome was followed by irreversible brain damage. Because there is a possible causal relationship between these events and treatment with lithium and neuroleptics, patients receiving combined therapy should be monitored closely for early evidence of neurological toxicity and treatment discontinued promptly if symptoms appear. This encephalopathic syndrome may be similar to or the same as neuroleptic malignant syndrome.
- SSRIs, sumatriptan and tricyclic antidepressants have been associated with episodes of neurotoxicity and may precipitate a serotonergic syndrome - either event justifies immediate discontinuation of treatment.
- Calcium channel blockers may lead to a risk of neurotoxicity in the form of ataxia, confusion and somnolence, reversible after discontinuation of the drug. Lithium concentrations may be increased or decreased.
- Carbamazepine or phenytoin may lead to dizziness, somnolence, confusion and cerebellar symptoms.
- Methyldopa

**Other interactions**

- Lithium may prolong the effects of neuromuscular blocking agents
- Thioridazine may increase risk of ventricular dysrhythmias
- Iodide and lithium may act synergistically to produce hypothyroidism
- There have also been case reports of lithium interactions with baclofen, co-trimoxazole, aciclovir and prostaglandin-synthetase inhibitors. The clinical significance of these interactions is uncertain.
4.6. Fertility, pregnancy and lactation

**Women of childbearing potential**

Effective contraception throughout lithium treatment should be considered and a joint decision between prescriber and patient should be made when considering continuation of lithium treatment in pregnancy.

**Pregnancy**

Pregnancy Category D:
Medicines which have caused, are suspected to have caused, or may be expected to cause, an increased incidence of human foetal malformations or irreversible damage. These medicines may also have adverse pharmacological effects. Accompanying texts should be consulted for further details.

The risk of birth defects may be increased when lithium is used during the first trimester. Second trimester detailed ultrasound examination and foetal echocardiography should be considered for women who have been treated with lithium during the first trimester of pregnancy. The newborn may show signs of lithium toxicity.

Lithium should not be used during pregnancy, especially during the first trimester, unless considered essential. Women of child-bearing potential should use effective contraceptive methods during treatment with lithium. There is epidemiological evidence that lithium may be harmful to the foetus in human pregnancy. Lithium crosses the placental barrier. In animal studies, lithium has been reported to interfere with fertility, gestation and foetal development.

Cardiac malformations, especially Ebstein abnormality, and other malformations have been reported.

In a meta-analysis of six cohorts of pregnant women and their children\(^1\), the absolute risk for infant cardiac malformation after exposure to lithium during the first trimester in the study by Patorno et al\(^1\) (2.4%) was similar to the absolute risk in the Munk-Olsen study\(^2\) (2.1%). A prenatal diagnosis, such as ultrasound and electrocardiogram examination, is strongly recommended. Treatment decisions between the prescriber and patient should be made as early as possible before conception. If a woman taking lithium wishes to become pregnant, consider stopping the medicine gradually over 4 weeks if she is well.

---

\(^1\) Patorno E et al. The New England journal of medicine. 2017 Aug 31;377(9):893-4

In certain cases where a severe risk to the patient could exist if treatment were stopped, lithium has been continued during pregnancy. Consider stopping lithium and restarting treatment after the first trimester or immediately post-partum. If it is considered essential to maintain Lithium Carbonate treatment during pregnancy, serum lithium levels should be monitored closely since renal function changes gradually during pregnancy and suddenly at parturition, requiring dosage adjustments. If lithium is used during organogenesis, foetal echocardiography and level-2 ultrasound should be performed. It is recommended that lithium be discontinued shortly before delivery and recommenced a few days post-partum.

Neonates may show signs of lithium toxicity including symptoms such as lethargy, flaccid muscle tone, hypotonia. Neonates showing signs of lithium intoxication may require fluid therapy in the neonatal period. Babies born with low serum lithium concentrations may have a flaccid appearance which returns to normal without any treatment. Careful clinical observation of the neonate exposed to lithium during pregnancy is recommended and lithium levels may need to be monitored as necessary.

**Breast-feeding**

Lithium should not be used during breast-feeding (see section 4.3). Lithium is excreted in breast milk, therefore bottle feeding is recommended. There have been case reports of neonates showing signs of lithium toxicity.

**Fertility**

See section 5.3.

**4.7. Effects on ability to drive and use machines**

Lithium may cause disturbances of the central nervous system (e.g. somnolence, dizziness, and hallucinations). Furthermore, at the beginning of treatment the occasional onset of fatigue can impair reflexes. Therefore, impaired driving performance or machine operation skills may occur in patients receiving lithium.

**4.8. Undesirable effects**

The occurrence and severity of adverse reactions are generally directly related to serum lithium concentrations as well as to individual sensitivity to lithium and generally occur more frequently and with greater severity at higher concentrations.

The most frequent adverse effects are the initial post-absorptive symptoms, believed to be associated with a rapid rise in serum lithium levels. They include gastrointestinal discomfort with mild nausea and diarrhoea, vertigo, muscle weakness and a dazed feeling and frequently disappear after stabilisation of therapy.

Fine tremor of the hands, thirst and polyuria may persist. Weight gain or oedema may present in some patients but should not be treated with diuretics.
Hypercalcaemia has been reported in about 10% of patients taking lithium. Hypermagnesaemia and hyperparathyroidism have also been reported. Skin conditions including acne, psoriasis, generalised pustular psoriasis, rashes and leg ulcers have occasionally been reported as being aggravated by lithium treatment.

Reversible ECG changes e.g. T wave flattening, or inversion, cardiac arrhythmias and EEG changes have been reported. Exacerbation of skin conditions (such as acne and psoriasis) and leucocytosis are relatively common side-effects of lithium therapy. Significant weight gain is also observed in many patients receiving lithium.

Long term administration of lithium carbonate may be associated with disturbances of thyroid function, including goitre, hypothyroidism and thyrotoxicosis. Lithium-induced hypothyroidism may be managed successfully with concurrent thyroxine.

Memory impairment may occur during long term use.

After a period lasting 3-5 years, patients should be carefully assessed to ensure that benefit persists.

Toxic effects may be expected at serum-lithium concentrations over 1.5 mmol/L, although they can appear at lower concentrations. They call for immediate withdrawal of treatment and should always be considered very seriously. Signs of toxicity include increasing diarrhoea, vomiting, anorexia, severe abdominal discomfort, polyuria, muscle weakness, lethargy, ataxia, lack of co-ordination, tinnitus, blurred vision, dry mouth, dysgeusia and impotence/sexual dysfunction, coarse tremor (marked) of the extremities and lower jaw, muscle hyperirritability and twitching, agitation, hyper-reflexia, choreoathetoid movements, dysarthria, disorientation, psychosis, drowsiness, seizures and coma. At higher concentrations, ataxia, tinnitus, blurred vision, giddiness and increasing polyuria are seen.

The following reactions appear to be related to serum lithium concentrations. Adverse reactions can occur in patients with serum concentrations within the therapeutic range (i.e. below 1.5 mmol/L or lower in the elderly). Adverse effects occurring at therapeutic serum lithium concentrations include anorexia, constipation or diarrhoea, epigastric discomfort, metallic taste, headache, vertigo, fine tremor, polyuria with polydipsia, and oedema.

The frequency at which reactions may occur are: Very common (1/10); common (1/100 to < 1/10; uncommon (1/1,000 to < 1/100); rare (1/10,000 to < 1/1,000; very rare (< 1/10,000)

| General disorders and administration site conditions | Unknown |
| Oedema |
| Cardiac disorders | Bradycardia, Sinus node dysfunction |
| Uncommon |
| Arrhythmia |
| Vascular disorders |

10 | Page
Rare
Unknown
Raynaud’s phenomena
Hypotension, Peripheral circulatory failure

Investigations
Uncommon
Unknown
Weight gain
ECG Nonspecific ST-T change

Skin and subcutaneous tissue disorders
Uncommon
Unknown
Hair loss, Acne, Skin rash
Folliculitis, itch, Exacerbation of Psoriasis, Angioedema

Endocrine disorders
Rare
Unknown
Hyperthyroidism
Euthyroid goitre, Hypothyroidism, Hyperglycaemia, Hypercalcaemia, hyperparathyroidism

Metabolism and nutrition disorders
Unknown
Hypermagnesimia, decreased appetite

Gastrointestinal disorders
Unknown
Nausea, vomiting, diarrhoea, gastritis, salivary hypersecretion, abdominal pain, dry mouth

Blood and lymphatic disorders
Unknown
Leukocytosis

Nervous system disorders
Rare
Unknown
Myasthenia gravis, dizziness
Tremor, fasiculation, ataxia, choreoathetosis, Reflexes tendon increased, Extrapyramidal disorders, syncope, seizures, Dysarthria, vertigo, Nystagmus, somnolence, stupor, coma, taste disorder, Scotoma, pseudotumour cerebri, Autonomic dysfunction, Vision blurred

Psychiatric disorders
unknown
Hallucinations

Musculoskeletal and connective tissue disorders
Muscle twitching

Reproductive system and breast disorder
Unknown
Impotence, Sexual dysfunction

Renal and urinary disorders
Unknown
nephrogenic diabetes insipidus

It is vital to bear in mind that lithium can be lethal, if prescribed or ingested in excess.

**Reporting of suspected adverse reactions**

Reporting suspected adverse reactions after authorisation of the medicine is important. It allows continued monitoring of the benefit/risk balance of the medicine. Healthcare professionals are asked to report any suspected reactions [https://nzphvc.otago.ac.nz/reporting/](https://nzphvc.otago.ac.nz/reporting/)
4.9. Overdose

**Symptoms**

In acute overdose, vomiting often occurs within an hour of ingestion due to the high concentration of lithium in the stomach, but significant amounts of lithium can still reach the systemic circulation. The typical clinical symptoms often appear after a latency period and gastrointestinal symptoms can re-appear at a later time. The symptoms of overdose are reported to be mainly related to the alimentary and nervous systems and include abdominal pain, anorexia, nausea, vomiting, occasionally mild diarrhoea, giddiness, tremor, ataxia, slurring speech, myoclonus, twitching, asthenia, depression, renal symptoms.

Coma and convulsions may occur in serious cases and cardiac effects (first-degree heart block and QRS and QT prolongation) have been described rarely. A patient may appear to be aware with open eyes but have an expressionless face and be unable to move or speak (coma vigil). Acute renal failure and nephrogenic diabetes insipidus may develop.

**Treatment**

Treatment is symptomatic and supportive; close monitoring of vital signs is recommended. Activated charcoal is of no value as it does not adsorb lithium. Whole bowel irrigation has been suggested, however, there are no clinical studies to confirm efficacy.

Further measures may involve procedures to enhance the renal clearance of lithium or its active removal. Adequate hydration should be ensured, and any electrolyte imbalance corrected but forced diuresis or diuretics should not be used (see Section 4.5). Appropriate supportive care may include measures to control hypotension and convulsions. Maintenance of fluid and electrolyte balance is particularly important because of the risk of hypernatraemia. The ECG should be monitored in symptomatic patients.

In severe poisoning, haemodialysis is the treatment of choice (particularly if there is renal impairment). Although effective in reducing serum-lithium concentrations, substantial rebound increases can be expected when dialysis is stopped, and prolonged or repeated treatments may be required. Peritoneal dialysis is less effective and only appropriate if haemodialysis facilities are not available. Haemofiltration has been tried to good effect.

Serum lithium concentrations should be monitored regularly throughout treatment. Once the serum and dialysis fluid are free of lithium, it has been recommended that serum-lithium concentrations should be monitored for at least another week so that allowance can be made for delayed diffusion from body tissues.

For advice on the management of overdose please contact the National Poisons Centre on 0800 POISON (0800 764766).

5. **PHARMACOLOGICAL PROPERTIES**
5.1. Pharmacodynamic properties

Mood-stabilising agent.

Pharmacotherapeutic group: Antipsychotics; Lithium ATC code: N05AN01

**Mechanism of action**

The exact mechanism of action of lithium in the treatment of bipolar disorders is not known. However, lithium modifies the production and turnover of certain neurotransmitters, particularly serotonin, and it may also block dopamine receptors. It modifies concentrations of some electrolytes, particularly calcium and magnesium, and it may reduce thyroid activity.

5.2. Pharmacokinetic properties

**Absorption**

Lithium ions are almost completely absorbed from the gastrointestinal tract, complete absorption occurring after about 8 hours. Peak plasma concentrations occur after about 2-4 hours.

**Distribution**

Lithium initially distributes into extracellular fluid and then to most other tissues. The final volume of distribution equals that of total body water. Lithium has a low volume of distribution (0.7 to 0.9 L/kg). It is not bound to plasma proteins.

Lithium slowly enters cerebrospinal fluid achieving at steady state 40% of the plasma concentration.

Lithium is not metabolised in the liver.

Lithium crosses the placenta and is excreted in breast milk.

**Elimination**

Occurs primarily via the kidneys (>95% of the dose), but lithium can also be detected in sweat and saliva. The elimination half-life is variable ranging from 18-36 hours. Lithium can be eliminated by haemodialysis.

**Special populations**

Elimination half-life may be increased in elderly patients due to age related decreases in renal function and also in patients with renal impairment (see sections 4.2 and 4.4).

5.3. Preclinical safety data

In animal studies, lithium has been reported to interfere with fertility, gestation and foetal development.
6. **PHARMACEUTICAL PARTICULARS**

6.1. List of excipients

Lithium Carbonate Capsules contain lactose monohydrate, maize starch, magnesium stearate, gelatin, EEC Quinoline Yellow E104, FD&C Blue #1 E133 and FD&C Yellow # E110.

6.2. Incompatibilities

Not applicable.

6.3. Shelf life

36 months.

6.4. Special precautions for storage

Store at or below 30°C.

6.5. Nature and contents of container

Lithium Carbonate 250mg Capsules: Bottle, plastic, HDPE, 100 capsules.

6.6. Special precautions for disposal and other handling

Any unused medicine or waste material should be disposed of in accordance with local requirements.

7. **MEDICINE SCHEDULE**

Prescription Medicine

8. **SPONSOR**

Douglas Pharmaceuticals Ltd
P O Box 45 027
Auckland 0651
New Zealand
Phone: (09) 835 0660

9. **DATE OF FIRST APPROVAL**
10. DATE OF REVISION OF THE TEXT

20 March 2023

Summary table of changes

<table>
<thead>
<tr>
<th>Section Changed</th>
<th>Summary of new information</th>
</tr>
</thead>
<tbody>
<tr>
<td>4.2</td>
<td>Wording corrections</td>
</tr>
<tr>
<td>4.3</td>
<td>Removed text “Diuretics should not be used during lithium therapy without appropriate dosage adjustment”</td>
</tr>
<tr>
<td>4.4</td>
<td>Added information in general section, on lithium toxicity, monitoring recommendations and renal impairment.</td>
</tr>
<tr>
<td>4.5</td>
<td>Added interaction with empagliflozin and dapagliflozin Reworded interactions and neurotoxicity section</td>
</tr>
<tr>
<td>4.6</td>
<td>Added information in pregnancy section. Removed duplicated information</td>
</tr>
<tr>
<td>4.8</td>
<td>Added information regarding oedema, weight gain, hypercalcaemia, hypermagnesaemia, goitre, hypothyroidism and thyrotoxicosis. Acne, psoriasis, generalised pustular psoriasis, rashes and leg ulcers have occasionally been reported as being aggravated by lithium treatment. Removed narrative AEs and replaced with tabulated AEs showing frequency where known Added “Memory impairment may occur during long term use.” Added “After a period lasting 3-5 years, patients should be carefully assessed to ensure that benefit persists.”</td>
</tr>
<tr>
<td>5.1</td>
<td>Added information on pharmacodynamic properties/mechanism of action</td>
</tr>
<tr>
<td>5.2</td>
<td>Added “Lithium has a low volume of distribution (0.7 to 0.9 L/kg). It is not bound to plasma proteins.” And “Lithium is not metabolised in the liver.” In distribution section. Updated elimination section with % of elimination and updated the elimination half-life and statement that lithium can be removed via haemodialysis.</td>
</tr>
</tbody>
</table>